Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Anemia, Refractory, with Excess of Blasts 3Leukemia 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory 1

Interventions

Cyclophosphamide 30fludarabine phosphate 25Cyclosporine 25Busulfan 20Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Cord Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Whole-Body Irradiation 15Radiotherapy 15Methotrexate 12Methylprednisolone 10Filgrastim 10Cytarabine 8Etoposide 7Tacrolimus 6Melphalan 6sargramostim 5fludarabine 4Thiotepa 4Granulocyte Colony-Stimulating Factor 4Decitabine 4Cyclosporins 4Azacitidine 4merphos 3Transplantation 3Arsenic Trioxide 3bryostatin 1 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × Amifostine × Classical hematology × Clear all
NCT00098683 2014-02-13

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Children's Oncology Group

Phase 2 Completed
10 enrolled
Classical hematologyMyeloid

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡